about
Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.Neural correlates of the psychedelic state as determined by fMRI studies with psilocybinDrug models of schizophreniaSensorimotor gating, cannabis use and the risk of psychosisAntipsychotic drug action: targets for drug discovery with neurochemical imaging.Functional neuroimaging in schizophrenia: diagnosis and drug discovery.Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literatureImaging the glutamate system in humans: relevance to drug discovery for schizophrenia.Proton magnetic resonance spectroscopy and illness stage in schizophrenia--a systematic review and meta-analysis.The glutamate hypothesis of schizophrenia: neuroimaging and drug development.Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosis.Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review.Long-Term Heavy Ketamine Use is Associated with Spatial Memory Impairment and Altered Hippocampal Activation.Disruption of frontal θ coherence by Δ9-tetrahydrocannabinol is associated with positive psychotic symptoms.Delta-9-tetrahydrocannabinol, neural oscillations above 20 Hz and induced acute psychosisAnterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophreniaTreatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive.Novel targets for drugs in schizophrenia.Glutamate and dopamine in schizophrenia: an update for the 21st centuryFunctional connectivity measures after psilocybin inform a novel hypothesis of early psychosis.HPA-axis function and grey matter volume reductions: imaging the diathesis-stress model in individuals at ultra-high risk of psychosis.Review: The biological basis of antipsychotic response in schizophrenia.Glutamate and psychosis risk.Cannabis in the arm: what can we learn from intravenous cannabinoid studies?The effect of sodium nitroprusside on psychotic symptoms and spatial working memory in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial.The blood-brain barrier in psychosis.Ketamine modulates subgenual cingulate connectivity with the memory-related neural circuit-a mechanism of relevance to resistant depression?Are we really mapping psychosis risk? Neuroanatomical signature of affective disorders in subjects at ultra high risk.Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo.An initial investigation of abnormal bodily phenomena in subjects at ultra high risk for psychosis: Their prevalence and clinical implications.Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology.Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?Delta-9-tetrahydrocannabinol disruption of time perception and of self-timed actions.Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis.Thalamic neurochemical abnormalities in individuals with prodromal symptoms of schizophrenia - relationship to auditory event-related potentials.Abnormal thalamic glutamate and liability to psychosis: state or trait marker?Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation.Neuroanatomical abnormalities that predate the onset of psychosis: a multicenter study.Glutamate, N-acetyl aspartate and psychotic symptoms in chronic ketamine users.
P50
Q24602238-0DA44B85-2EF6-4D14-8BC0-FA4FA1EB6C29Q24633222-71C0E4B6-7816-43C3-995C-47E60B2822EFQ28084198-3057A332-3A77-482D-8AC7-69BA2942B4F8Q30411076-57D6E861-1DE1-4A45-B582-F4797832F11CQ31032036-D925A8BD-3D17-4038-BD01-CDF90A73C14BQ31142480-99D4C605-43BB-4B08-8EA4-D4E37BC791E0Q31147797-321A6D5E-717B-45D4-B740-B435ABCEE9CCQ33494673-B01A6645-5951-47B6-A645-58EB17A177C9Q33767237-D5B0217F-3809-4178-AE7E-1EC43BF37B00Q34143117-493ABA83-424C-47F0-9747-4628550230F9Q34270086-47A9326E-D652-4F05-9033-9D930E17B052Q34304341-EE069BBA-9385-442A-B67C-9EE185C4DD21Q34607053-77CD58C3-8133-423C-8D8D-8E46492FFB0BQ34630511-AF4B6925-B0B6-45CF-AD96-E8D16BBF6677Q34662055-3EFF0A21-5111-40FA-BD30-C99D0EDE7CD2Q34996731-0EEE223C-BFEB-4D88-9657-775BF7FC94CEQ36234271-6EFF3CC8-0120-4BBE-BF8E-8B7554496D44Q36817154-5DE812D8-8BA2-48F9-9D88-582F5E884AD7Q36907403-8D143BE3-B202-489A-8EF9-CDAAE003C5C7Q36992322-F46CFBDF-ED45-461A-8220-B4D8E0CE4C42Q37228293-8E964F45-9A6A-4B5D-ADF9-C6DF6D186F47Q37349833-9A9B86B8-31CD-4073-8AC9-004D9D8E8D51Q37638930-37FAD19E-7ACC-48A8-8714-586DEFD3DD0EQ37975268-B589F3BC-008B-44FE-9E5E-D339DF7AC85CQ38020214-5A3E8A4C-8A20-441D-8AF3-F8F8074C9BFFQ38387298-0C627A13-BB1D-4554-9FA6-603B26CC7F7EQ38646326-E8AE9777-C7E4-461D-81EE-6C3C19490207Q38647409-D28748DF-3A30-42EA-A6DB-54169AAAE7DCQ39153105-0DE3A104-61C8-4D35-8F39-12C58FC31329Q40408851-883D087D-DB0D-4F70-9546-2486EDFEB830Q40843532-CE8AABD8-398E-4774-98F3-6E8497575AE8Q41853824-5B954EC2-E89C-4ADC-AAFF-F0BD488157EDQ42544021-BE176DB8-A6DC-4BE2-ADF5-D1F5B1C51861Q42961273-21852A0E-BD9D-4F12-927A-125AFFA97702Q42967481-96A20297-C712-4B41-8F44-21B1BD6D5B86Q42974369-1B07CD0E-BED1-4669-ACF0-E2B72ED0E94FQ43280308-FF6BDC45-5247-40AA-A130-B90DE9BEAACFQ43760503-90CFB7B5-79E2-48E0-8777-C0507CD3E351Q43851337-D9A4DF63-BBA3-4463-980D-60BE93915FF0Q44560334-4421CF0E-25AD-4717-88B6-5C62E2849FE5
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
J M. Stone
@nl
J M. Stone
@sl
James Stone
@en
James Stone
@es
type
label
J M. Stone
@nl
J M. Stone
@sl
James Stone
@en
James Stone
@es
altLabel
J M. Stone
@en
prefLabel
J M. Stone
@nl
J M. Stone
@sl
James Stone
@en
James Stone
@es
P106
P1153
35254619400
P21
P31
P496
0000-0003-3051-0135